<DOC>
	<DOCNO>NCT02129933</DOCNO>
	<brief_summary>To improve detection esophageal ( pre ) malignant lesion surveillance endoscopy patient risk develop malignancy , example Barrett 's Esophagus ( BE ) , need good endoscopic visualization ability target biopsy . Optical molecular imaging neoplasia associate biomarkers could form promise technique accommodate need . It known biomarker Vascular Endothelial Growth Factor ( VEGF ) overexpressed dysplastic neoplastic area BE segment versus normal tissue proven valid target molecular imaging . The University Medical Center Groningen ( UMCG ) develop fluorescent tracer label VEGF-targeting humanized monoclonal antibody bevacizumab , currently use anti-cancer therapy , fluorescent dye IRDye800CW . We hypothesize bevacizumab-IRDye800CW administer , accumulate VEGF express high grade dysplasia ( HGD ) esophageal adenocarcinoma ( EAC ) , enable early cancer visualization use newly develop fluorescent NIR fiber-bundle . This hypothesis test pilot intervention study .</brief_summary>
	<brief_title>VEGF-targeted Fluorescence Near-Infrared ( NIR ) Endoscopy ( Pre ) Malignant Esophageal Lesions</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Identified HGD intramucosal EAC ( T1 ) therefore candidate endoscopic mucosal resection therapy Mentally competent person , 18 year old . Written informed consent . Adequate potential followup . Medical psychiatric condition compromise patient 's ability give inform consent . Submucosal invasive EAC ; EAC tumorclassification T1 . Concurrent ( uncontrolled ) medical condition disqualify endoscopic mucosal resection procedure . Previously perform therapeutic endoscopic procedure . Pregnancy breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>EAC</keyword>
	<keyword>HGD</keyword>
	<keyword>Esophagus</keyword>
</DOC>